CLSN - Earnings call transcript Q4 2021

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, and welcome to Celsion’s Fourth Quarter and Year-End 2021 Earnings Call. My name is Jess and I will be your operator today. At this time, I would like to remind everyone that this call is being recorded. I would now like to turn the conference over to Monique Kosse, LifeSci Advisors. Please go ahead, ma’am.

Monique Kosse

good and Jess, you, morning, everyone. Thank Celsion for the today, XXXX. issued ended a results financial announcing release fourth XX, press December Earlier quarter year and

may Financial Chairman, CEO website President of the With You Jeff today and release Church, and Investors Chief us Tardugno, the tab. company’s Michael are Celsion; that access Officer. under on

a Following remarks, will we session. management’s open question-and-answer prepared the call for

Exchange results President. except during like call, XX, Chairman, the undertakes I’d and Michael? obligation no the This be turn will discussion. expectations Generally, the uncertainties, operations, These management of over In current call, this or outlook required could accurate can is other the financial be With the Celsion set content by statements can and about the this forward-looking to periodic results subject of Commission. comments and be about of today, XXXX. at this including based statements and or the any guaranteed Celsion’s means Michael and number of in call today’s and the making live expectations and contemplated made as and During March regarding is on impact statements differ there such forth the events. results statements. projections pandemic. No COVID-XX those is future Tardugno, estimate such risks now broadcast duration date statements conference materially to believes, revise on by call CEO expects, to best from update impact actual forward-looking filings identified Celsion’s information and time uncertainty for terminologies of on COVID-XX forward-looking are a company’s significant to that, change are of anticipates, may particular, based expressions. Also only as as similar Securities law. with the the

Michael Tardugno

Good morning, Thank everyone. you, Monique.

will our the Nicholas who Anwer, Science with participate quarter at year-end Financial question-and-answer and Jeffrey Dr. our Khursheed Officer; and Officer, remarks. is Medical Church, today review me of results of Borys, our following Chief Chief the session the Chief Officer, in both are call. end whom will Joining Also today our Dr. my fourth us

look I it an company, a in to incredible have XXXX, we development back as I As made on our say report I’m was pleased progress significant programs. to year. the have that particularly

I our As our noted evaluated lead have vaccine releases, press in our achieved being report development can milestones key in our And ovarian we’ve important we GEN-X Phase clinical in from initiative. not observed that II study. results cancer plasmid compound DNA

into taken we’ve Now, first your research on and before to that me discuss I let steps development future I’ve go recent company. ensure progress, our – the more detail of that

support shares we of twofold. which from of received February for consolidation, recently our stock executed Special voted was than Meeting of XX% During our Shareholders, more the goal

First, Stock importantly, maintain split and was NASDAQ on Exchange. listing necessary very the our stock the reverse to

ongoing by effectively million authorized business. now available stock up freed excluding number shares the conduct the some from XXX have to consolidation, Second, shares of we

new two, number in shares capital to assets opportunistically years form few raise has research; our also raised the sure capital made over to We’ve example, past the add options on remained align terms I’m that For the you to needed one, would of shareholders. of having our three, provide with our management and/or number and to strong, to to employees support number our to and agree. pipeline; if to sheet hire acquire that sure interests talent balance

readout runway reserves And non-dilutive be plus value-creating In sufficient three-plus objectives. to – important the progression-free another sales XXXX Phase other our anticipated see with operating net with that’s cover fund through us study, $X had and and all, PFS can We’re among in very completed. ovarian million shareholder-friendly. in projections of our the that the We million enough an to survival, company operating closed to $XX current over Jersey cash the cash. New years of XXXX loss spending through NOLs II confidence to provide unrestricted cancer

to turning programs, in immune for or are of we advancing both platforms, Now two system development an of delivery DNA focused on plasmids important four which are response. our use technology synthetic recruiting

Our synthetic delivery technology. non-viral first our DNA TheraPlas is platform,

of therapeutic Our doing entirety early despite first system inflammatory incorporates with to product impressive and some is future IL-XX, ability the plasmid anti-cancer our by the encoded vaunted shown the becomes replete GEN-X that we on GEN-X. entry immune-oncology platform COVID-XX an promising recruit GEN-X challenges represents call an protein candidate activity. tumor TheraPlas the important for so has pro the microenvironment the oncology significant of immune the trials. And pandemic. in immune and into and

moving exciting significant We progress clinical product candidate this have made forward in trials.

cancer ovarian and II XX% year. enrollment the X Phase enrolled quarter in Our complete with to expected is newly third of women, this OVATION is diagnosed in over advanced study

primary study. zero the as resection in have as the We arm among reported, scores a have and for These undergone over encouraging in survival, our our zero improvement PFS, XX% demonstrated improvement portends we is well debulking as results showing seen surgery. interval patient the first the that have XX resection who control a patients patients, endpoint previously, reported arm the significant GEN-X treatment as

Borys’ for novel on under this has patients complementary entitled X meet coming needs He benefit leaving advertorial website. the and the OVATION being also Now to unturned is direction, cancer taking targets. and highlights our trial print in for the Dr. participating created We’ve development stone clinical completing month ovarian team no today notes clinical an study where in a in of enrollment treatment markets conducted. arranged paper a our clinical action in a issued all The study our focused insert be the USA of study. will trial. is This for

patients repeat I’ll to it’s in becoming a that, trial www.ovariancancerstudy.com. of for you participant. study our www.ovariancancerstudy.com. potential Let and the informs you, I site me to go and encourage say that that

recruit a PFS or XX participant. to quarter, I third the complete indication to study XXX the later by registrational X And XXXX, end We the to attractive occur, pursue among months allows. to the we of at if application study potential which study survival, the The Favorable the OVATION August. end we’ll mean, study XXX the an quite various than the puts of comes patients highlight progression-free in the to time and on when the trial a continue time the If find in August, scientific that, all third no GOG for think readout you’ll GEN-X meetings. on patients would explaining it optimistic we a that’s other up of This third results median will XXX track I our from final up in intraperitoneal quarter. data minimum of and before remain anticipate of enrollment complete we become accelerated expect provides We and enrolling achieve around and results to XX quarter for also occurs, that mean, will XXX of is patients. patients requirements study the the the evaluation whichever cancers. other PFS patients for data, events first.

off. is antigens our PLACCINE. this our And technology to next-generation our is paying experience a has second plasmid. our or one single I Moving that call vaccine pathogens of which with adaptation we technology more express on can certainly is PLACCINE TheraPlas platform the platform, that multiple say to potential proprietary an in technology for

vaccine developed is for platform first the being candidate a for using formulated proof-of-concept initiative comparator. evaluation commercial on product mRNA this effective Our as a preclinical baseline COVID-XX in highly

ever-changing vaccine to virus other such for delivery is the mRNA improves against of normal morphology. flexibility a factors, demonstrate a storage variants independence at from to DNA, can that COVID-XX the the to of longer-lasting superiority viral value of and expect of antigens, to goal the quickly manufacturing vaccine of expression an function a COVID-XX, and distribution to or protect Our a of the as over which protection respond as with time, vaccine, temperatures device as DNA’s multiple administer longer-lasting potential cost-effective show among we function simplified stability attributes, DNA-based need a

announcing upcoming to two from easily antigens evolving plans vectors, months, vaccine more T-cell for COVID-XX, over which like ability has three the stay responses our resulted accomplishments. to address end, to a variants. XX spike ability non-human with to impressive of express our you production out be successfully to the and primate optimize studies have DNA produced antibodies of four showing at and the that vaccine and conferences, specific some to various in XX To the I’d with cytotoxic viral have months, we will different point the along quickly most goal of next to our virus antigens past results preclinical ask that as flexible develop We plasmid handful over tuned the an or and

data variants commercial discussions preclinical been have in addressing to with shows vaccines. scientific highly antibody with and Our titer them. advisors and vectors effective equivalent the DNA way, the commercial, data, of supported These shared both by two mRNA our our

and include we now strong methods an now vaccine supported scientists new have evaluation. As internal team, by continue a Scientific for forward, We Board. scientific Advisory having product six competencies with backgrounds in-house analysis our analytical

And established for applied with novel compositions relationships companies have capability. vaccine their finally, use. that vaccine patents and enabling have in development have We discovery for we

a with the arm five study forward in scientific non-human moving primate NHP now vernacular. We’re that’s

animals among quarter to vaccine and lasting Moving second a vaccine inoculation by plan primate period. response tomorrow a I with year. more our forward arm, response looking is the data see fourth NHP over with quarter protection durability than in expect to ability, additional What data of commercial to designed the study control these potential with in the comparator. six-month a preliminary the We this and mean a non-human study, of mRNA begin five we’re

excited up to for our more gotten requires our investment range would strong with the the of this Assuming success, commercialization epidemic company, in product to COVID-XX infectious potential for vaccine potential. importantly, market, you would given of opportunity success with partnering platform current But we’ve research the opportunity the in development mean is that and how forward for look address to assuming a bring or commercial area. Very COVID this again, the obviously community disease we expand the company the marketplace. competency to that vaccine pandemic application successful. a the can’t we from in competitors of support like we’re tell that I exciting discussions

the towards capabilities, FDA internal and will we flexibility and trials, have our project manufacturing have advantage forward plasmid both and technologies, cover of look we that As course in-house agencies plasmid assuming these products. medicine and With we clinical to in-house cost commercial markets, approval. two European manufacturing successfully a GEN-X for developing world-class initiated for both needs a answer successful

Now our welcome XX, we XXXX opportunity Jeff, you. turn I’d the on to call before note where like I Annual the platform holding to Shareholder we discuss to our over be June that and technologies progress with will Meeting

this do hold the not Our current us hold we person. participate thinking meeting past, it in in you we to We and we in change. have circumstances the to the is do if welcome as join hope But in person, meeting.

us. Jeff manufacturing capabilities we opportunity believe to We’re potential deepening Church, success With longer-term are scientific of on the approach call internally our commercial commercial approaches, two that a bench Jeff? strategically I’ll view before review the blockbuster turn for we capabilities a and opportunity. We our a methodically excited for and and R&D are that, toward building meaningful over path has with the financials, success. by With that the with

Jeffrey Church

million of outstanding a stock. stock been On preferred completed stock offering convertible morning additional redeemable shares value-creating and outstanding. additional deducting Jersey from net milestones. the in in longer these no market outstanding you, preferred company’s losses. with support million an in March Form of respect We’ve is of Celsion our proceeds press we million XX-K, is which adding sale year included in to were XXXX, which financial $XX has are believe important Michael. and funding raising their the securities raised stock. position our to ended X, an and February one several equivalent common our from XXXX and we offering $X.X we before Also operating January year anticipate In New the other Thank the redeemed XXXX NOLs, before program innovative $XX.X The the with full we liquidity and sale XXXX XXXX of $XX.X receivable. over our direct of cash short-term through operating retired us to in was interest $X.X to million investments We placement quarter filed timeframe. from in million State this the Details the issued only We release non-dilutive fourth cash, in year-end an results all of are expenses. to Preferred agencies XXXX, open. expenses. this registered excellent we position

to XXXX. our sufficient fund through end operations capital resources have We of the

turn me to our review financial let Now statements. of year-end a

insurance million to $XX.X $X.X the million. the development as Celsion and decreased PLACCINE loss year. million from increased lower administrative ended $X.X platform XXXX, development in attributable $XX the which due higher the of was a $X.X $X.X period supplies. million This X of CMC year the year in Research $X.X expenses of clinical to million in technology XXXX. associated increase costs decreased $XX.X net study year. associated in to to million stock compared in the OVATION primarily levels $XX.X to XXXX. to to and expenses non-cash Research and clinical manufacturing development XXXX, million regulatory Operating last General to in compensation loss million, with XXXX, same million of last compared support were compares million, July fees of approximately study $X.X with $XX.X in For fees in prior expense director GEN-X OVATION well million vaccine by net billion of XXXX X $X.X to in the costs this December largely of we XXXX of OPTIMA the professional the call reported at XX% million. with XXXX, reported the DNA increase to increased in XX, $X.X year-to-year on in the that, XXXX turn XXXX. as million meritless costs and in Other legal $X.X represented III and million back now a With is $XXX,XXX. defend suits consistent XXXX, filed Costs expenses various opposition which million approximately increase in the $XXX,XXX in results $X.X premiums development And Phase increase from were and to $XX.X a compared and Michael. after clinical to an I’ll were $XX.X XXXX. and million of announcement

Michael Tardugno

goal with members patients, call their our gene-mediated for immunotherapy comprehensive technologies, PLACCINE overview open We shareholders and I’d you, closing, platform to proceed immune-oncology, Jeff, like and clinicians, to developing like would vaccine our I’d providing of in TheraPlas the open support we exciting initiative. everyone, lines, unwavering in forward financials. our Thank our and your Q&A. look that, exciting please? very In now and you Operator, updates. thank, Board our to for to as of And the our

Operator

Our [Operator first Brookline question comes Kumaraguru Certainly. Instructions] from Markets. Capital Thank at you.

go Please open. is line Your ahead.

Kumaraguru Raja

for Thanks questions. my taking

think because for the is where PFS that’s to PFS XX regard you patients either that expectation And look are the right in so terms study, you with later going I to for it at months? to XX So at months, the these also, event the are follow OVATION what of seeing have far? you

Michael Tardugno

Yeah.

Borys So PFS. on I’m gong do ask to a Dr. comment

the I just think But a have statisticians Nick, answer we would look. that, we’ve our and please? you care give a to – to handful asked us

Nicholas Borys

Yeah, thank you for much that very question.

median know, XX PFS started be or to PFS patients and gearing many we is results. monitoring And you of these up PFS months. average as the So the around

of the to And last enrolled. so that we events around we this the very early or after XX maybe to At patients XX maybe get have bulk expect XX time, date. months

early as And to me. numbers early for on way exact speculate be GOG trend mature, sure have promising better a But it as don’t GEN-X go. probably showing interesting was more way results you. look you But could the would with And and reviewing meeting. arm. at that we’ll front in with our ASCO and we’ll Partners share that too tell, that which I the are of We to the becomes be data the

Kumaraguru Raja

Okay.

in months the these on for is So patients. XX of the of data follow-up all third assumption based it’s quarter

Michael Tardugno

on In the the median XX months time study.

Kumaraguru Raja

are to Okay, platform, at studies? with going to And regard this construct look got PLACCINE what you the it. primate

Michael Tardugno

a question. That’s good

group we different think please? I options. give had one-to-one us a on with considered a can our advisory option could with and this detail, concluded would line, – you the And scientific on of mRNA long address comparator the on heads in most the a discussion we comparison more we important number comparator. here Khursheed with the that you

Khursheed Anwer

vector of one into Michael that NHP game. Thank moving a conformational goals Yes. the that as you, one a for study very vaccines so, European data. excellent mouse to this virus said, DXXXG at the Wuhan proof-of-concept expresses animals the close Kumar, And NHP commercial the Michael. to through type would are larger from is the wild variant, the that do be

the to demonstrate animals mouse, think but would where commercial the the goal larger I that identical the variant to So close very vaccine, is also not the be it that’s to that right comparison vaccine. commercial only activity in to going with compare from

have apples-to-apples that’s the an that’s chronic multiple multiple that’s you vector, eventually we’ll close do the compared as we to So lead antigens, factor antigen have commercial comparison, purpose, with well. vector, test vector. But our to very that although

Kumaraguru Raja

Khursheed, please? study various of the you arms the of overview give they’re what are us little of And addressing, can and comprised a what

Khursheed Anwer

Thank you, Yes. Michael.

will. We

the there So of study the Kumar. placebo. arms are five One is

Of animals. course, non-vaccinated

Then mRNA comparator comparable human comparator expressing antigen two Our given second the the vector doses. vaccine. dose SARS-CoV-X the that’s single our been group at is to that a if at antigen

have to been at the make how to compared the that will least then mRNA antibodies then reduction, them up, to group two, virus. titers and And ability groups neutralization the the one dose the doses. can titer the ability the animals is mRNA then the viral fourth And of or to we the – at competitors, these look and durability. some are group, IgG. two demonstrate by beyond. affected levels if antibody control vaccine. injecting the the fifth if compared compared that at four will then these to which so And months viral vaccine be their to would group take and fifth dose challenge of So have the at viral vaccine vaccinated, means with infection, then our does to animals not built that protect point after duration against response of see the They’re also you six And see

So measuring we up And will that be that then collecting blood six months. time, levels group. and at antibody we’ll to fifth challenge

three is objectives, third So it confirmatory the mouse to NSB; from the secondary, compare to does durability. and comparator; how

Michael Tardugno

And assumption hypothesis durable I DNA that a to please, capability. may our bit the ask vaccine just want I Kumar, more to protective Khursheed? may, you Khursheed have a for Can if to another address a that speak

Khursheed Anwer

Michael. Sure,

antigen protein, you’ll say, Kumar, and expression So or we profile clear protein an times. mRNA, a see encoding at or if DNA inject, muscle, very into in antigen distinction

So for immunity building protein divide. episomal antigen days, lasts known. a matter very that the and from But you’re mRNA protein of of a against. nucleus in in off very become Inherently, well hours, don’t muscles expression DNA quickly mRNA DNA, disappears the couple it’s with

very time. long expression the period for lasts So a of

less. as expression early XX You hours do get as or

probably of translate responses to So response, antigen exposure sustain boosting, they’re into exposure that’s or right? antigen the at like gone. a So least immune kick important immune durability could, long-lasting could also longer is but off the

the sustain time. a second response in or whatever as theory, if the for to could, But a period You lasts longer long boost, you of boost. antigen antigen period time, immune for third, the of do

Kumaraguru Raja

Thank That’s you. very helpful.

Nicholas Borys

to they’re three can two vaccine And response, four that challenging. shortcomings others everybody the our here of two think certainly months that we’re of commercially or durability major that every I the ourselves is the requires a agree attempting subjecting course, is address to among – that shortcomings revaccination challenging,

one to the that’s and that we’re So attempting address. major issue

some as address ability the may ability to as result, this protective see we virus, see more of designed than the construct. second capabilities, And variant. for. one for hands what is as The others We have this the as these our new in vaccine change variants not the a to originally particular is quite and virus in be strong of a vaccine

a But in methods plasmid say nucleic acid position another delivery program ways just in our new is I approach So this with ideally potential for vaccines. have exciting in hands, our to times. to vaccine, – with our in and have hands, experience many development a the to is way, synthetic put And superior DNA address in us vaccine everyone us. to

Kumaraguru Raja

Okay.

Operator

We’ll go Bautz Zacks Small David with next Research. Cap to

is open. go ahead. Your Please line

David Bautz

morning, the morning. everyone. for Thanks this good update Hey,

you’re because be were first I’m questions study. see And on into you resection. are curious OVATION out going few getting So ads that patients surgical data to curious enrolled if my also if for going I’m on additional the X the trouble putting to any mentioned we’re recruitment. study, having you

Michael Tardugno

Yeah.

direction the Omicron caused At to expense our fact, institutions who of the the question the variant than a the Omicron the that’s a address on I study, study in enrolling variant patients this, enrolling recruitment. me or the initiated a enrollment XX When ago, maybe about XX And XXXX. let or to of first. little recruitment. the that with on question we’re number the of hospitals little So we’ve in resources times the a longer we with of last patients are surgence ago, originally that the we focus of from a first with investigators know sites talked the that resurgence presenting of a for or we on complete The the – with Phase disappointed at healthcare focus expected II our first multiple the virus. year-and-a-half pandemic. quarter we’re portion patients year-and-a-half their our don’t

are result projecting, activity. a we’ve we a that, seen in of resurgence now As

to has always will our to think enrollment of N us. We’re beginning. that conclude more better, quarter. The The in lobbying more us confidence third study Dr. bit the opportunity than is that information Borys patients now the it’s projecting with data. gives and we as many of been makes right as lot We from sense recruit target a XXX more enroll – a bigger from can patients. a

relatively to And and it call nominal say, advertorial, deal so Nick a patients sense a the in of more period this relatively a we before during advertisement, study. just have chance to nominal we cost me But Nick, time this conclude at in to of to us. all great made have the treat I cost, We negotiated patients. GEN-X short didn’t get a better let We this. think evaluate these a relatively

So all in all, it do. was a cost-effective way the to increase the thing right N. We think to it’s

I think, more gives by exposure visibility, we’re the with more us II recruit assuming Phase more III a to way, to it gives successful the us study Phase opportunity trial.

want probably that – Nick, think if to that? to you add your you But answers I do more any question.

Nicholas Borys

cancer Yeah. To to we for everything medical recruitment so a question, done follow-ups. the forth. we’re can as there’s over have we’ve But to advertise. been been use an go last absolutely, their social to checkups, Meanwhile, And decrease pleased in very that in knows think have media during opportunity COVID, and the hesitant anybody people result, the we many that in incidence I a world year.

as been hits research as well And result so that’s And reported. that well. clinical a

to and do going hopefully, Meanwhile, studies. normal our get from recruitment this get can quickly to awareness patients we to Celsion possible everything COVID very And clinical research. and is world into So back recovers impact create the rates.

David Bautz

are more doctors bit delaying their with of advanced question. who our are presenting But patients seeing little more And, and those is disease, Nick, a than you your right? information also physicians, just along from lines this

Nicholas Borys

correct. that’s Yeah,

And here, anybody so, it’s time do checkup, for again, listening please if to it. your

delay to anything want in and and checkups don’t if of You terms screening. follow-ups

advanced as because in ovarian wait, the know, of cancer, And important cancer treat cases tougher longer very you the you. to present ovarian the it with in especially is that’s XX% So you disease.

So I think to everyone fronts. that’s understand it very know on that many important impacts for and

you’re about Going question, resection asking surgical rates. to your first

manage reported we was in that studies. an GEN-X that future prompted GOG in the the trial, catalyst and today And Michael its XX% to and comments, do We continue that – helping reported for rates. resection improvement. there’s in the a that join improvement the company the for his II registrational prepare Partners Phase us As prepared patients surgical with study us he see to to the

is that But it’s FDA. important by an endpoint secondary recognized a it’s because So not the point.

is endpoint primary the Our PFS.

an So very data very important see continue improvement. us. is The to that’s to the that’s and surgical going be encouraging rate we to resection

Michael Tardugno

– just to have patients your information. question, get be the some to bolus – report we we had as prepared who debulking another additional your And specifically to interval surgery, of will

David Bautz

what of the Thanks to great. Okay, for missed I primate I’m that’s study? underway, study in the going And sorry, getting are this, be regards for if that. to to using challenge non-human but strain SARS-CoV-X going be

Michael Tardugno

believe, DXXXG, that right, Sorry, is I Khursheed?

Khursheed Anwer

XXX virus the first Yes, happened to type in single glycine Michael. appeared This the sporadic wild is that at Wuhan and position. mutation Europe where the acid mutated was

string. Very the string. close to alpha the So is that’s

David Bautz

didn’t reason the right to strain test a Omicron now? why that’s for out since you there want Is there Okay. it’s

Khursheed Anwer

Yeah.

pointed earlier Michael that vectors. out XX As made different we have

discussion comparison least comparison internal should lot study for it competitor with was be made We Board, a with to equal important of And with this But you that on commercial one, then have with of vaccine. a with and our the want it a discussion commercial if the Scientific advised the make was goals virus. Advisory same footing than at have strain vectors one of Omicron. to the

for reason variant. more or also, subjects with purpose. maybe we our down a the not that’s new that vector, bicistronic enrolling exclude But some So the road do

change variant. it of of talk today, course, but town to the is Omicron course, different a the Of may

Our technology today. Omicron of is goal is proof-of-concept the clearly, show prevalent but and vaccine our to relation competitor, to a

do to want you vector. anything a to have add Michael, We it.

Michael Tardugno

way to test is to us designed don’t order our approved been use equivalence are DXXX address for say superiority, or another it clearly for for establish the the I have want wanted I emergency do. coded And just vaccines in variant. – variant. the plasmid the we to to that same

coded our that a There’s So plasmid nothing future, goal show for from the to the study superiority is that’s in here us existing variant. over to has vaccine the prevent developing Omicron with this vaccines. a

David Bautz

Okay.

If into would do you partner? vaccine alone move you you that to potentially? would going were only Or clinic, with do a it candidate the this

Michael Tardugno

That’s go a makes to think we’re We a clinic question partner discussing that we the with the the – opportunity potential internally. for to success. greatest

You can do quickly. lot a it more

clinical in is cancer. experience in research Our largely

we be of take not it, on research So it’d area do clinical It’s we understanding just couldn’t little bit new part. that a for would us. our more a

So be for partner our a to goal for clinical will look research.

David Bautz

great. Okay, taking for this questions Thanks the well, morning.

Michael Tardugno

you. Thank

Operator

Mr. I’ll questions turn holding, no With to the Tardugno closing conference any remark. or back other for additional

Michael Tardugno

to conference you developments want we are of being the important continuing call progress as two see that’s We much for look you you attending forward very and advising conducted indications. Celsion. about thank occurs. that very for and hope as to very excited our by I in I your all in work can to again, the the interest So company our

So as near I end very said some relatively call. remarks, be future. to tuned. our Thanks will in updates expect We we stay that, presenting very in the do interesting my earlier And again with much.

Operator

We does gentlemen, participation. your Thank Ladies conclude today’s and thank for you that call. you.

may disconnect time. You at this

Imunon (IMNN) 31 Mar 222021 Q4 Earnings call transcript